Drug shortages remain a serious problem for patient safety, according to newly published results from a survey of pharmacy directors. Nearly half of the responding directors reported adverse events at their facilities.
The Ohio State University Wexner Medical Center is one of 18 clinical research centers taking part in a national study to establish guidelines for safely stepping down treatment in patients whose asthma is well controlled.
New drugs offer significant advantages, but payers must define payment approaches for optimal utilization. Three key thought leaders discuss this and more in our exclusive roundtable.
A recent Bloomberg News story stated that Express Scripts plans a specialty drug price war over new hepatitis C treatments. That news follows the release of a new drug, sofosbuvir (Sovaldi, Gilead), which reportedly costs $1,000 per pill.
Editorial Questions? Contact the Editorial Team. Click Here.
Sales, Reprints, Classified questions? Contact the Sales Team. Click Here.
